Skip to content

Gyre Therapeutics

Primary Menu

About
Science
Investors
Contact

Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy

Post navigation

Previous: Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog alfa in Hemophilia B

Next: Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports On-Demand Treatment in Hemophilia A Mice

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

About
- Management Team
- Board of Directors
Science
Investors
Contact

Gyre Therapeutics

Gyre Therapeutics, Inc.
| 12770 High Bluff Drive, Suite 150,
San Diego, CA 92130

© Gyre Therapeutics, Inc. All rights reserved.
Terms of Use Privacy Policy

X

Previous

Next